Announcement PDF Market Announcement 29 October 2026 29 October 2026 35 8.0 Market Announcement 1/1 Neurizon Therapeutics Limited (ASX: NUZ) – Trading Halt Trading in the securities of Neurizon Therapeutics Limited (‘NUZ’) will be halted at the request of NUZ, pending the release of an announcement by NUZ. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of: • the commencement of normal trading on Monday, 2 November 2026; or • the release of the announcement to the market. NUZ’s request for a trading halt is attached below for the information of the market. Issued by ASX Supervision 1854 6.0 Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222 29 October 2026 Monique Burley Adviser, Listings Compliance (Perth) ASX Compliance Pty Limited Central Park, 152-158 St Georges Terrace Perth WA 6000 By email only: tradinghaltsperth@asx.com.au Dear Monique, REQUEST FOR TRADING HALT Neurizon Therapeutics Limited (ASX: NUZ) (the Company) requests an immediate halt to the trading of the Company’s ordinary shares (NUZ) quoted on the Australian Securities Exchange (ASX) to apply from the open of trading today, Thursday, 29 October 2026, in accordance with ASX Listing Rule 17.1. The trading halt is requested pending an announcement by the Company to the market regarding the outcome of a proposed capital raising (stated purpose). In accordance with ASX Listing Rule 17.1, the Company provides the following information in relation to the request: 1. The trading halt is necessary to assist the Company in managing its continuous disclosure obligations as the Company expects to make an announcement to the market in relation to the stated purpose above. 2. The Company requests that the trading halt remain in place until the earlier of commencement of normal trading on Monday, 2 November 2026, or when the announcement regarding the stated purpose is released to the market. 3. The Company expects to make the announcement regarding the stated purpose to the market before the commencement of normal trading on Monday, 2 November 2026. 4. The Company is not aware of any reason why the trading halt should not be granted or of any further information necessary to inform the market about the trading halt. Please contact me if you require any further information concerning this matter. Yours sincerely, Stefan Ross Company Secretary Neurizon Therapeutics Limited